# **EC DECLARATION OF CONFORMITY**

### without the participation of a Notified body - diagnostic medical devices in vitro

Pursuant to Section 13(2) of Act No 22/1997 Coll., on the Technical Requirements for Products, and on a change and addition to certain laws, as amended, and pursuant to Directive 98/79/EC of the European Parliamenta nd of the Council of 27 October 1998 on *in vitro* diagnostic medical devices, the requirements of which have been adopted by Government Regulation 56/2015 Coll., on Technical Requirements for *in vitro* Diagnostic Medical Devices, as amended

#### **MANUFACTURER**

# GeneProof a.s., Vídeňská 101/119, Dolní Heršpice, 619 00 Brno, Czech Republic www.geneproof.com

hereby declares that following product

## **GeneProof Aspergillus PCR Kit**

Medical device type:

Classification:

Intended purpose of the device:

*in vitro* diagnostic medical device other diagnostic medical devices

The kit is an *in vitro* nucleic acid amplification test intended for detection of *Aspergillus spp.* (*A. fumigatus, A. flavus, A. niger, A. oryzae, A. candidus, A. foetidus, A. nidulans, A. ustus, A. versicolor, A. wentii, A. clavatus, A. niveus*) and *A. terreus* in the clinical specimens: BAL, CSF, plasma, serum, sputum, whole blood. The kit is intended to use in combination with a manual or automated extraction system. The kit is designed for human in vitro diagnostics and provides qualitative detection. The kit is intended for diagnostics, and aid for diagnosis and it is designed for professional use in laboratories with trained staff. The target population is the EU population. The intended testing population is immunocompromised

individuals.

Variants: ASP/ISEX/025, ASP/ISEX/100

complies with the basic requirements of Annex No. 1 of the Directive 98/79/EC of the European Parliament and of the Council and the Czech Government Regulation No. 56/2015 Coll. and under normal use it is safe and effective for its intended purpose. The manufacturer has taken measures assuring compliance of all medical devices introduced into the market with their technical documentation and with the essential requirements.

Following currently valid version of the standards were applied to meet essential requirements:

ČSN EN ISO 13485 ed.2:2016

ČSN EN ISO 14971:2020

ČSN EN ISO 18113-1:2012

ČSN EN ISO 18113-2:2012

CSN EN ISO 18113-2:2012

ČSN EN ISO 15223-1:2017

ČSN EN ISO 23640:2016

Medical device – QMS – Requirements for regulatory purposes

Medical device – QMS – Application of risk management to medical devices

In vitro diagnostic medical devices -- Information supplied by the manufacturer (labelling) -- Part 1 Terms, definitions and general requirements

In vitro diagnostic medical devices -- Information supplied by the manufacturer

(labelling) -- Part 2 In vitro diagnostic reagents for professional use Medical devices – Symbols to be used with medical device labels, labelling and

information to be supplied, Part1: General requirements

In vitro diagnostic medical devices – Evaluation of stability of in vitro diagnostic reagents

Procedure described in Annex No. 3 of the Directive 98/79/EC of the European Parliament and of the Council and the Czech Government Regulation No. 56/2015 Coll. were used to evaluate the basic characteristics of the product by the designated method.

Brno, May 18, 2022

Kamil ŠPLÍCHAL

Quality Assurance/Regulatory Affairs

Chief Quality and Regulatory Affairs Office

**Chief Quality and Regulatory Affairs Officer** (Name, position and signature of authorized person)

Manufacturer's stamp:



Version: DOC\_1092\_A02\_1.0
Effective date: 18, 5, 2022
Annex EN\_4.0\_1.6, 2020
E - Controlled Document
Overs 1.11

